Please ensure Javascript is enabled for purposes of website accessibility

Why MacroGenics, Inc. Stock Is Heating Up Today

By George Budwell - May 16, 2019 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MacroGenics shares jumped in response to another major clinical update today.

What happened

MacroGenics (MGNX 4.36%), a small-cap cancer-therapy company, saw its shares rise by as much as 14.6% in early morning action today. The biotech's stock perked up in response to another positive clinical update for the late-stage breast cancer candidate margetuximab. 

This time around, margetuximab reportedly produced a superior progression-free survival rate in HER2-positive metastatic breast cancer patients -- who have previously been treated with anti-HER2-targeted therapies -- than the current standard of care consisting of Roche's Herceptin plus chemotherapy. The data reportedly come from the Phase 3 trial known as SOPHIA. The drugmaker's shares have pulled back slightly from their intra-day highs, but they were still up by 10.1% as of 12:01 p.m. EDT. 

A male doctor explaining a chart to a female patient who is sitting upright in a hospital bed.

Image source: Getty Images.

So what

Breast cancer therapy is on track to become a $10 billion drug market by 2025. So, even as a later-line treatment for a particular segment, margetuximab should have no trouble raking in at least several hundred million in sales. Moreover, there are no treatments approved by the Food and Drug Administration for patients who have stopped responding to the current cohort of front line anti-HER2-targeted therapies. Margetuximab would thus fill an important unmet medical need -- one that should come with a built-in competitive moat. 

Now what

MacroGenics plans on giving a more thorough clinical update on SOPHIA's progress at next month's American Society of Clinical Oncology meeting. Meanwhile, this small-cap drugmaker is sure to start making the rounds on the buyout rumor mill. Breast cancer drugs with a well-differentiated clinical profile are a highly coveted commodity in the pharma world, after all.

Whether or not a buyer steps into the picture, MacroGenics' shares should have more room to run from here based on margetuximab's hefty commercial opportunity. Therefore, risk-tolerant investors might want to consider buying into this intriguing growth story soon.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics, Inc. Stock Quote
MacroGenics, Inc.
MGNX
$4.31 (4.36%) $0.18
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$40.37 (0.62%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.